Shares of the pharma giant AstraZeneca (NASDAQ:AZN) advanced in Thursday’s early trading hours on better-than-expected third-quarter results, fueled by strong cancer drugs sales. Further, the company lifted its full-year guidance on strong year-to-date business performance and 19 approvals bagged since the Q2 earnings call in July. AZN stock gained more than 4% on NASDAQ in the pre-market trading session. Also, the stock is up 4.7% so far this year. Adjusted earnings of $1.67 per share surpassed the analysts’ consensus estimate of $1.52 and increased 55% from the same quarter last year. Further, revenue climbed nearly 11% to $11 billion and beat the Street’s expectations of $10.8 billion.
https://www.tipranks.com/news/astrazeneca-nasdaqazn-stock-rises-on-upbeat-q3-results-guidance-lift?utm_source=advfn.com&utm_medium=referral
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Jan 2023 bis Feb 2023 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Feb 2022 bis Feb 2023 Click Here for more AstraZeneca Charts.